At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Deucravacitinib (drug), Placebo matching deucravacitinib (other)
- How long the study runs
- Study runs about 150 months (dates as stated)
- About the drug or intervention
- Deucravacitinib — drug: Specified dose on specified days · Placebo matching deucravacitinib — other: Specified dose on specified days
- Patient visit burden
- Not specified by the sponsor
In plain English
This study, run by Bristol-Myers Squibb, looks at drug levels, how well a medicine called deucravacitinib works, and how safe it is in children and teenagers aged 4 to under 18 with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes raised, scaly patches. Participants who finish the Week 52 treatment period in Part A or B may continue into a long-term extension period.
Who can take part
- Males and females aged 12 to under 18 (Cohort 1) or aged 4 to under 12 (Cohort 2)
- Have had plaque psoriasis for at least 6 months
- Have moderate to severe disease
- Could be treated with light therapy (phototherapy) or medicine that affects the whole body (systemic therapy)
- Must have completed the Week 52 treatment period in Part A or B to join the long-term extension period
Who may not be able to
- Weighing 30.0 kg or less (Cohort 1) or under 18.0 kg (Cohort 2) at screening
- Having other forms of psoriasis
- A history of recent infection
- Having taken deucravacitinib (BMS-986165) or another active comparator before
- Evidence of active TB (tuberculosis) for the long-term extension period
- Other study rules may also apply — ask the trial team
What taking part involves
- • Taking the study medicine deucravacitinib so researchers can measure drug levels, how well it works, and its safety
- • A treatment period lasting up to Week 52 in Part A or B, with a possible long-term extension afterwards
- • Not stated — ask the trial team
Time commitment: The trial involves at least 52 weeks of treatment, plus a possible long-term extension; details of visits and tests are not stated — ask the trial team.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 4 Years to 18 Years
- Who
- All
- Number of participants
- 153
- Started
- 2021-03-23
- Last checked
- 2026-08
Plain English Summary
What is this study?
- • Testing a new treatment for plaque psoriasis
- • Phase3 - 153 participants
- • The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis
Who can take part?
- • Ages 4 Years to 18 Years
- • Diagnosed with plaque psoriasis
Where?
- • London - Local Institution - 0029
- • Connor Downs - Mounts Bay Medical
- • London - Local Institution - 0092
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort. Part A will evaluate the drug levels of BMS-986165 to enable selection of 2 dose levels to be studied in Part B. Part B will assess the efficacy and safety of two dose levels in children and adolescent participants with moderate to severe plaque psoriasis. The 5-year long-term extension (LTE) period will observe the long-term safety and tolerability of deucravacitinib in children and adolescent participants with psoriasis who have completed Parts A or B of the study.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 4 Years - 18 Years
- Who can join: All genders
Treatment history
Treatments you must have had:
- ✓ completed the Week 52 treatment period in Part A or B for long-term extension (LTE) period
What the study is looking for
- ✓Inclusion Criteria
- ✓Males and females aged 12 to \<18 years for Cohort 1. Males and females aged 4 to \<12 years for Cohort 2.
- ✓Plaque psoriasis for at least 6 months.
- ✓Moderate to severe disease.
- ✓Candidate for phototherapy or treatment that goes through your whole body.
See the full criteria
Where Is This Study? (3 UK sites)
Local Institution - 0029
London WC1N 3JH, United Kingdom
Mounts Bay Medical
Connor Downs TR27 5DT, United Kingdom
Local Institution - 0092
London SE1 7EH, United Kingdom
How to Get in Touch
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Sponsor contactCONTACT
First line of the email MUST contain NCT # and Site #.
Sponsor contactCONTACT